The FDA has released draft guidance on how sponsors can use Bayesian models for clinical trials.
Ideally, specific treatment for a cancer patient is decided by a multidisciplinary tumor board, integrating prior clinical experience, published data, and patient-specific factors to develop a ...
The guidance encourages the use of Bayesian statistics in drug trials. Instead of starting from scratch and only adding new ...
The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...
WASHINGTON, Jan. 20, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued new draft guidance modernizing statistical methodologies used in clinical trials, formally recognizing ...
Many antineoplastics are designed to target upregulated genes, but quantifying upregulation in a single patient sample requires an appropriate set of samples for comparison. In cancer, the most ...